Chemogenomics: drug discovery's panacea?
- PMID: 16880939
- DOI: 10.1039/b603004c
Chemogenomics: drug discovery's panacea?
Abstract
Chemogenomics aims towards the systematic identification of small molecules that interact with the products of the genome and modulate their biological function. This Opinion article summarizes the different knowledge-based chemogenomics strategies that are followed and outlines the challenges and opportunities that will impact drug discovery. Chemogenomics aims towards the systematic identification of small molecules that interact with the products of the genome and modulate their biological function. While historically the approach is based on efforts that systematically explore target gene families like kinases, today additional knowledge-based systematization principles are followed within early drug discovery projects which aim to biologically validate the targets and to identify starting points for chemical lead optimization. While the expectations of chemogenomics are very high, the reality of drug discovery is quite sobering with very high project attrition rates. This article summarizes the different knowledge-based chemogenomics strategies that are followed and outlines the challenges and potential opportunities that will impact drug discovery.
Similar articles
-
Discovery on Target 2006 - CHI's fourth annual event. Chemogenomics: small molecules as biological probes.IDrugs. 2007 Jan;10(1):30-2. IDrugs. 2007. PMID: 17187311 No abstract available.
-
Chemogenomics approaches to novel target discovery.Expert Rev Proteomics. 2007 Jun;4(3):411-9. doi: 10.1586/14789450.4.3.411. Expert Rev Proteomics. 2007. PMID: 17552925 Review.
-
Current parallel chemistry principles and practice: application to the discovery of biologically active molecules.Curr Opin Drug Discov Devel. 2009 Nov;12(6):899-914. Curr Opin Drug Discov Devel. 2009. PMID: 19894197 Review.
-
Exploring the chemogenomic knowledge space with annotated chemical libraries.Curr Opin Chem Biol. 2004 Aug;8(4):412-7. doi: 10.1016/j.cbpa.2004.06.003. Curr Opin Chem Biol. 2004. PMID: 15288252 Review.
-
Chemogenomics: structuring the drug discovery process to gene families.Drug Discov Today. 2006 Oct;11(19-20):880-8. doi: 10.1016/j.drudis.2006.08.013. Epub 2006 Sep 7. Drug Discov Today. 2006. PMID: 16997137 Review.
Cited by
-
Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors.PLoS Comput Biol. 2009 May;5(5):e1000387. doi: 10.1371/journal.pcbi.1000387. Epub 2009 May 15. PLoS Comput Biol. 2009. PMID: 19436720 Free PMC article.
-
Microfluidic-Based Multi-Organ Platforms for Drug Discovery.Micromachines (Basel). 2016 Sep 8;7(9):162. doi: 10.3390/mi7090162. Micromachines (Basel). 2016. PMID: 30404334 Free PMC article. Review.
-
Determining the Degree of Promiscuity of Extensively Assayed Compounds.PLoS One. 2016 Apr 15;11(4):e0153873. doi: 10.1371/journal.pone.0153873. eCollection 2016. PLoS One. 2016. PMID: 27082988 Free PMC article.
-
Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery.Drug Discov Today. 2017 Jul;22(7):994-1007. doi: 10.1016/j.drudis.2017.02.004. Epub 2017 Mar 6. Drug Discov Today. 2017. PMID: 28274840 Free PMC article. Review.
-
Biomarker discovery and clinical proteomics.Trends Analyt Chem. 2010 Feb 1;29(2):128. doi: 10.1016/j.trac.2009.11.007. Trends Analyt Chem. 2010. PMID: 20174458 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources